Mainz Biomed N.V. and Dante Genomics announced the formal commencement of ColoAlert's consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante's extensive database and sold via Dante's, region-specific, ecommerce websites.
Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.